
News|Articles|January 1, 2011
FDA Pipeline Preview, January 2011 (Ezogabine, Ticagrelor, Naltrexone SR/bupropion, Clostridium difficile vaccine, Elacytarabine, Glycerol phenylbutyrate, Perifosine, Cladribine Tablets, Florbetapir, ALS-AVP-21D9, Cyclosporine, PRX-8066, QLT091001)
Recent FDA action (through, December 2010) related to Ezogabine, Ticagrelor, Naltrexone SR/bupropion, Clostridium difficile vaccine, Elacytarabine, Glycerol phenylbutyrate, Perifosine, Cladribine Tablets, Florbetapir, ALS-AVP-21D9, Cyclosporine, PRX-8066, QLT091001.
Advertisement
Complete response
Recommended for approval
Fast-track designation
Orphan drug designations
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Two studies underscore need for more effective, bladder-sparing therapies in high-risk cancer
2
Keytruda shows survival edge over Tecentriq, Opdivo in older patients with lung cancer
3
COVID-19 vaccines could help tumors respond better to immune checkpoint inhibitors
4
Gilead’s Single-Tablet HIV Regimen Meets Primary Endpoints
5

















































